Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

68°
- Benton, AR (72018)
  Today
  
  Mostly clear. Low near 60F. Winds SSW at 5 to 10 mph..
  
  Tonight
  
  Mostly clear. Low near 60F. Winds SSW at 5 to 10 mph.
  
  Updated: November 14, 2025 @ 6:22 pm
- Full Forecast

- Site search

Home
News
- Local News
Sports
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
Archives
Readers Choice 2025

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

SpringWorks Therapeutics, Inc. - common stock (NQ:SWTX)

46.99 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about SpringWorks Therapeutics, Inc. - common stock

< Previous 1 2 3 4 5 6 Next >

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 28, 2023

Via Benzinga

SpringWorks Catapults 24% On A 'Watershed Moment' In Cancer Treatment ↗

November 28, 2023

The company gained FDA approval for Ogsiveo, a treatment for desmoid tumors.

Via Investor's Business Daily

PDD Posts Upbeat Revenue, Joins Avidity Biosciences, SpringWorks Therapeutics And Other Big Stocks Moving Higher On Tuesday ↗

November 28, 2023

U.S. stocks traded mixed, with the Dow Jones gaining around 10 points on Tuesday.

Via Benzinga

Topics Stocks

Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗

November 28, 2023

Shares of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults...

Via Benzinga

Analyst Ratings for SpringWorks Therapeutics ↗

August 24, 2023

Via Benzinga

Analyst Ratings for SpringWorks Therapeutics ↗

July 20, 2023

Via Benzinga

The Latest Analyst Ratings for SpringWorks Therapeutics ↗

June 06, 2023

Via Benzinga

FDA Approves SpringWorks Therapeutics' Lead Therapy As First For Subtype Of Soft Tissue Sarcomas ↗

November 28, 2023

The FDA approved SpringWorks Therapeutics Inc's (NASDAQ: SWTX) Ogsiveo (nirogacestat), an oral gamma-secretase inhibitor, for adult patients with progressing desmoid tumors who

Via Benzinga

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

November 27, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

HC Wainwright & Co. Maintains Buy Rating for SpringWorks Therapeutics: Here's What You Need To Know ↗

November 20, 2023

Via Benzinga

What's Going On With Rare Diseases-Focused SpringWorks Therapeutics Stock Today? ↗

November 16, 2023

SpringWorks Therapeutics Inc (NASDAQ: SWTX) released topline results from its Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with...

Via Benzinga

SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN

November 16, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

SpringWorks Therapeutics: Q1 Earnings Insights ↗

May 03, 2023

Via Benzinga

Analyst Expectations for SpringWorks Therapeutics's Future ↗

April 20, 2023

Via Benzinga

SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

November 02, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting

November 01, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer

September 11, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

SpringWorks' Investigational Cancer Treatment Is Standard Care, Analyst Unfazed By FDA Update ↗

August 24, 2023

In March, the FDA issued SpringWorks Therapeutics Inc (NASDAQ: SWTX) with a Form 483 letter due to a failure to ensure that the analysis of an exploratory endpoint in the Phase 3 DeFi trial, which...

Via Benzinga

SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

August 02, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

June 07, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA

June 05, 2023

FDA Extending PDUFA Date by Three Months to Allow More Time to Complete Their Review; New PDUFA Date Set to November 27, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

June 01, 2023

EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END

Via FinancialNewsMedia

SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors

May 30, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting

May 25, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit

May 24, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress

May 11, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 03, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

SpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference

May 02, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

April 17, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023

April 17, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Announcements
e-Edition
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

bentoncourier.com
321 North Market Street
Benton, AR 72018
Phone: 501-315-8228
Email: bcadmin@bentoncourier.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Benton, AR (72018)

Today

Tonight

SpringWorks Therapeutics, Inc. - common stock (NQ:SWTX)

All News about SpringWorks Therapeutics, Inc. - common stock

Sections

Services

Follow Us